Baird Financial Group
MRNA icon

Baird Financial Group’s Moderna MRNA Stock Holding History

Baird Financial Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$835K Buy
11,918
+7,137
+149% +$369K ﹤0.01% 1387
2026
Q1 		$243K Buy
+4,781
New +$223K ﹤0.01% 1708
2024
Q3 		– Sell
-2,016
Closed -$239K – 1801
2024
Q2 		$239K Sell
2,016
-50
-2% -$6.33K ﹤0.01% 1623
2024
Q1 		$220K Sell
2,066
-4,536
-69% -$457K ﹤0.01% 1648
2023
Q4 		$657K Sell
6,602
-1,877
-22% -$158K ﹤0.01% 1272
2023
Q3 		$876K Sell
8,479
-1,533
-15% -$171K ﹤0.01% 1153
2023
Q2 		$1.22M Buy
10,012
+150
+2% +$20K ﹤0.01% 1054
2023
Q1 		$1.51M Sell
9,862
-2,856
-22% -$471K ﹤0.01% 976
2022
Q4 		$2.29M Buy
12,718
+1,006
+9% +$164K 0.01% 837
2022
Q3 		$1.39M Buy
11,712
+4,313
+58% +$654K ﹤0.01% 956
2022
Q2 		$1.06M Buy
7,399
+2,120
+40% +$303K ﹤0.01% 1063
2022
Q1 		$909K Sell
5,279
-1,109
-17% -$187K ﹤0.01% 1186
2021
Q4 		$1.62M Sell
6,388
-2,516
-28% -$736K ﹤0.01% 1012
2021
Q3 		$3.43M Sell
8,904
-1,318
-13% -$486K 0.01% 734
2021
Q2 		$2.4M Buy
10,222
+328
+3% +$58.6K 0.01% 843
2021
Q1 		$1.3M Buy
9,894
+7,683
+347% +$1.11M ﹤0.01% 1036
2020
Q4 		$231K Buy
+2,211
New +$224K ﹤0.01% 1462

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Baird Financial Group's MRNA Position: Q2 2026 in Review

Baird Financial Group increased its Moderna (MRNA) stake by 149% in Q2 2026, buying an estimated $369K and bringing the position to 11,918 shares worth $835K. The position accounts for ﹤0.01% of the portfolio, ranked #1387.

Baird Financial Group first reported a position in MRNA in Q4 2020 and has held it in 17 quarters since. The position peaked at $3.43M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Baird Financial Group held 11,918 shares of Moderna worth $835K as of Q2 2026.
  • Baird Financial Group bought 7,137 Moderna shares in Q2 2026, an estimated $369K.
  • Moderna made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1387 holding.
  • Baird Financial Group first reported a position in Moderna in Q4 2020 and has held it in 17 quarters since.
  • Baird Financial Group's Moderna position peaked at $3.43M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.